

LITHUANIA

National Health Insurance Fund under the Ministry of Health of the Republic of Lithuania

(+37052364100, vlk@vlk.lt)

Pharmaceutical pricing and reimbursement policies in the in- and out-patient sector

OUT- PATIENT

IN - PATIENT

	OUT- PATIENT	IN - PATIENT
PRICING at ex-factory level	<p>Pricing in the out-patient reimbursement</p> <p>Statutory pricing</p> <p><u>Pricing policies for reimbursable medicines</u> External price referencing: Declared manufacturer price is compared with 95 % of the average manufacturer prices in reference countries (8 countries)</p> <p>The first generic is required to be priced 50% below the originator. The second and the third follower required to set their prices 15% lower than the cheapest product and the following ones need to be cheaper</p> <p>The first biosimilar is required to be priced 30% below the originator. The second and the third follower required to set their prices 10% lower than the cheapest product and the following ones need to be cheaper</p>	<p>Pricing in the in-patient sector (Public hospital)</p> <p>Negotiations Committee under the Ministry of Health</p> <p>Price negotiations</p> <p>Expensive hospital medicines included in the List of Centrally Procured Medicines and Medical Devices (centrally purchased by the NHIF)</p> <p>Free pricing</p> <p>Hospital medicines not included in the List of Centrally Procured Medicines and Medical Devices</p>
	<p>PRICING at wholesale and pharmacy level</p> <p>Statutory pricing</p> <p>Wholesales Regressive margins</p> <p>Pharmacies Regressive margins</p> <p>VAT: 5% for reimbursable medicines, 21% for non-reimbursable medicines</p>	<p>Tendering Price negotiations</p> <p>Expensive hospital medicines included in the List of Centrally Procured Medicines and Medical Devices All hospital medicines</p> <p>Statutory margins are not relevant, unless products are from community pharmacy</p> <p>VAT: 5% - reimbursed medicines 21% - not reimbursed medicines</p>
REIMBURSEMENT	<p>Reimbursement in the out-patient sector</p> <p>Positive list (500 active substances included on positive list)</p> <p>Reference price system (RPS)</p> <p>ATC 5 & 4 level (Lowest price of medicine in reference group)</p> <p>Percentage co-payment 10%, 20%, 50% of reimbursed rate, depends on severity of the disease (the more severe, the higher the reimbursement rate), 100% reimbursed medicines has co-payment until 1.5 EUR (depends on retail price, exception Insulins)</p> <p>Mechanisms for vulnerable groups 100 % reimbursed rate for all reimbursed medicines for children, disable patients</p> <p>Reforms MEA: price volume, expenditure cap, risk sharing</p> <p>E-prescriptions system</p>	<p>Reimbursement in the in-patient sector</p> <p>Expensive hospital medicines included in the List of Centrally Procured Medicines and Medical Devices (26 active substances)</p> <p>Out-patient list also relevant for in-patient sector</p> <p>Medicines are integrated in the lump sum (with some exceptions) which can be generated for reimbursement</p> <p>Hospital formularies are not centralized Pharmaceutical formulary per hospital</p> <p>No co-payment in hospitals</p> <p>Reforms price negotiations with manufactures or wholesalers strategy for the acquisition of patented expensive hospital drugs</p>